CN116888115B - 二氟甲基-吡啶-2-基三唑 - Google Patents

二氟甲基-吡啶-2-基三唑

Info

Publication number
CN116888115B
CN116888115B CN202180066477.8A CN202180066477A CN116888115B CN 116888115 B CN116888115 B CN 116888115B CN 202180066477 A CN202180066477 A CN 202180066477A CN 116888115 B CN116888115 B CN 116888115B
Authority
CN
China
Prior art keywords
pain
compound
pharmaceutically acceptable
disorders
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180066477.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN116888115A (zh
Inventor
F·蒙特尔
Y·崔
N·海涅
O·赫克尔
R·利平斯基
S·彼得斯
J·S·拉森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aniona APS
Original Assignee
Boehringer Ingelheim International GmbH
Aniona APS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20189671.9A external-priority patent/EP3950683A1/en
Priority claimed from EP20197363.3A external-priority patent/EP3971179A1/en
Priority claimed from EP20204664.5A external-priority patent/EP3992188A1/en
Application filed by Boehringer Ingelheim International GmbH, Aniona APS filed Critical Boehringer Ingelheim International GmbH
Priority to CN202511122723.3A priority Critical patent/CN120943817A/zh
Priority to CN202511122672.4A priority patent/CN120943816A/zh
Publication of CN116888115A publication Critical patent/CN116888115A/zh
Application granted granted Critical
Publication of CN116888115B publication Critical patent/CN116888115B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202180066477.8A 2020-08-05 2021-08-04 二氟甲基-吡啶-2-基三唑 Active CN116888115B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202511122723.3A CN120943817A (zh) 2020-08-05 2021-08-04 二氟甲基-吡啶-2-基三唑
CN202511122672.4A CN120943816A (zh) 2020-08-05 2021-08-04 二氟甲基-吡啶-2-基三唑

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20189671.9A EP3950683A1 (en) 2020-08-05 2020-08-05 Difluoromethyl-pyridin-2-yl triazoles
EP20189671.9 2020-08-05
EP20197363.3 2020-09-22
EP20197363.3A EP3971179A1 (en) 2020-09-22 2020-09-22 Difluoromethyl-pyridin-2-yl triazoles
EP20204664.5A EP3992188A1 (en) 2020-10-29 2020-10-29 Difluoromethyl-pyridin-2-yl triazoles
EP20204664.5 2020-10-29
PCT/EP2021/071755 WO2022029170A1 (en) 2020-08-05 2021-08-04 Difluoromethyl-pyridin-2-yl triazoles

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202511122723.3A Division CN120943817A (zh) 2020-08-05 2021-08-04 二氟甲基-吡啶-2-基三唑
CN202511122672.4A Division CN120943816A (zh) 2020-08-05 2021-08-04 二氟甲基-吡啶-2-基三唑

Publications (2)

Publication Number Publication Date
CN116888115A CN116888115A (zh) 2023-10-13
CN116888115B true CN116888115B (zh) 2026-03-20

Family

ID=77447863

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202180066477.8A Active CN116888115B (zh) 2020-08-05 2021-08-04 二氟甲基-吡啶-2-基三唑
CN202511122672.4A Pending CN120943816A (zh) 2020-08-05 2021-08-04 二氟甲基-吡啶-2-基三唑
CN202511122723.3A Pending CN120943817A (zh) 2020-08-05 2021-08-04 二氟甲基-吡啶-2-基三唑

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202511122672.4A Pending CN120943816A (zh) 2020-08-05 2021-08-04 二氟甲基-吡啶-2-基三唑
CN202511122723.3A Pending CN120943817A (zh) 2020-08-05 2021-08-04 二氟甲基-吡啶-2-基三唑

Country Status (7)

Country Link
US (1) US20230286946A1 (https=)
EP (3) EP4596558A3 (https=)
JP (3) JP7802256B2 (https=)
CN (3) CN116888115B (https=)
ES (1) ES3061465T3 (https=)
PL (1) PL4192823T3 (https=)
WO (1) WO2022029170A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240425491A1 (en) 2021-05-05 2024-12-26 University College Cardiff Consultants Limited Heteroaryl compounds useful in the treatment of cognitive disorders
AU2022327398A1 (en) * 2021-08-12 2024-03-21 Shanghai SIMR Biotechnology Co., Ltd Substituted triazole derivative, preparation method therefor, pharmaceutical composition thereof, and use thereof
EP4514348A4 (en) * 2022-04-29 2025-12-31 Noetix Pharma Llc PREVENTION AND TREATMENT OF POSTOPERATIVE COGNITIVE DYSFUNCTIONS (POCD)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104411703A (zh) * 2012-06-26 2015-03-11 萨尼奥纳有限责任公司 苯基三唑衍生物及其调节gabaa受体复合体的用途
CN110248940A (zh) * 2017-02-01 2019-09-17 菲尼克斯药品股份公司 芳基烃受体(AhR)调节剂化合物
WO2020016443A1 (en) * 2018-07-20 2020-01-23 Boehringer Ingelheim International Gmbh Difluoromethyl-phenyl triazoles as gaba receptor modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8742097B2 (en) * 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
CA2876778A1 (en) * 2012-06-26 2014-01-03 Saniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001279A1 (en) * 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
MA53158A (fr) 2018-07-20 2021-05-26 Aicuris Gmbh & Co Kg Procédés de criblage et d'identification d'agents inhibant ou modulant le complexe de sortie nucléaire du virus de l'herpès

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104411703A (zh) * 2012-06-26 2015-03-11 萨尼奥纳有限责任公司 苯基三唑衍生物及其调节gabaa受体复合体的用途
CN110248940A (zh) * 2017-02-01 2019-09-17 菲尼克斯药品股份公司 芳基烃受体(AhR)调节剂化合物
WO2020016443A1 (en) * 2018-07-20 2020-01-23 Boehringer Ingelheim International Gmbh Difluoromethyl-phenyl triazoles as gaba receptor modulators

Also Published As

Publication number Publication date
EP4192823B9 (en) 2026-03-18
EP4596559A2 (en) 2025-08-06
JP7802256B2 (ja) 2026-01-20
JP2025168356A (ja) 2025-11-07
JP2025168355A (ja) 2025-11-07
PL4192823T3 (pl) 2026-04-07
EP4596559A3 (en) 2025-11-05
CN116888115A (zh) 2023-10-13
EP4192823A1 (en) 2023-06-14
ES3061465T3 (en) 2026-04-06
EP4192823B1 (en) 2025-12-17
WO2022029170A1 (en) 2022-02-10
TW202220971A (zh) 2022-06-01
EP4192823C0 (en) 2025-12-17
JP2023536511A (ja) 2023-08-25
EP4596558A3 (en) 2025-11-05
EP4596558A2 (en) 2025-08-06
US20230286946A1 (en) 2023-09-14
CN120943816A (zh) 2025-11-14
CN120943817A (zh) 2025-11-14

Similar Documents

Publication Publication Date Title
AU2022202372B2 (en) Pyrimidin-2-ylamino-1H-pyrazols as LRRK2 inhibitors for use in the treatment of neurodegenerative disorders
CN112424197B (zh) 作为gaba受体调节剂的二氟甲基-苯基三唑类
RU2573560C2 (ru) Производные арилэтинила
AU2019382504B2 (en) Cyclic ureas
CN116888115B (zh) 二氟甲基-吡啶-2-基三唑
US10695334B2 (en) Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors
EP2702050B1 (en) Pyrazolidin-3-one derivatives
EP2513102A1 (en) Ethynyl derivatives
CN120202199A (zh) Mc4r拮抗剂化合物、药物组合物及其在医药上的应用
EP4638437A1 (en) Phenylpiperidine derivatives as inhibitors of glutaminyl-peptide cyclotransferase and glutaminyl-peptide cyclotransferase like protein
TWI915398B (zh) 二氟甲基-吡啶-2-基三唑
HK40129488A (en) Difluoromethyl-pyridin-2-yl triazoles
EP3971179A1 (en) Difluoromethyl-pyridin-2-yl triazoles
EP3992188A1 (en) Difluoromethyl-pyridin-2-yl triazoles
EP3950683A1 (en) Difluoromethyl-pyridin-2-yl triazoles
AU2012247654B2 (en) Pyrazolidin-3-one derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20251207

Address after: Grosschup Autonomous city, Gyeonggi Region, Denmark

Applicant after: ANIONA APS

Country or region after: Denmark

Address before: Ingham, Germany

Applicant before: BOEHRINGER INGELHEIM INTERNATIONAL GmbH

Country or region before: Germany

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant